Last 35.00 GBp
Change Today +1.75 / 5.26%
Volume 285.2K
EKF On Other Exchanges
As of 11:35 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

ekf diagnostics holdings plc (EKF) Snapshot

35.00 GBp
Previous Close
33.25 GBp
Day High
35.00 GBp
Day Low
34.00 GBp
52 Week High
01/20/14 - 43.00 GBp
52 Week Low
07/25/13 - 23.75 GBp
Market Cap
Average Volume 10 Days
-0.41 GBp
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ekf diagnostics holdings plc (EKF) Related Businessweek News

No Related Businessweek News Found

ekf diagnostics holdings plc (EKF) Details

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the United Kingdom, the United States, Germany, Poland, Russia, Ireland, and Asia. The company offers near patient analyzers for the detection and management of diabetes, anemia, lactate, and kidney related diseases. Its products include glycated hemoglobin analyzers, such as Quo-Test, Quo-Lab, and Biosen HbA1c analyzers for monitoring diabetes; hemoglobin analyzers consisting of Hemo Control, Hemo Speed, and Hemo Vet, which are point of care devices to provide results for hemoglobin and hematocrit, as well as STAT-Site M Hgb, a hand-held device for blood screening programs; and glucose and lactate analyzers comprising Biosen C-Line and S-Line glucose and lactate analyzers, and Lactate Scout+, a hand-held lactate analyzer. The company also provides rapid testing services, including pregnancy tests, such as True20, QuPID, and QuStick for urine only or urine and serum pregnancy testing; and infectious diseases tests, such as H. Pylori, RELY Mono, RELY and Strep A, and QuStick for the detection of pathonogenic micro-organisms, such as bacteria, parasites, viruses, and fungi. In addition, it offers clinical chemistry reagents; and biomarker diagnostic kits used by researchers and clinicians. The company sells its products to GP surgeries, pharmacies, blood banks, sports clinics, hospitals, and laboratories through a network of distributors. EKF Diagnostics Holdings plc was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

330 Employees
Last Reported Date: 02/26/14
Founded in 1990

ekf diagnostics holdings plc (EKF) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 224.0K GBP
Executive Chairman
Total Annual Compensation: 44.0K GBP
Chief Financial Officer, Secretary and Direct...
Total Annual Compensation: --
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 184.0K GBP
Compensation as of Fiscal Year 2012.

ekf diagnostics holdings plc (EKF) Key Developments

EKF Diagnostics Holdings plc Announces Board Changes

EKF Diagnostics Holdings plc announced that Mr. Paul Foulger, who re-joined the Board as Interim Finance Director in July 2013, has agreed to join the Company on a permanent basis with effect from 11 April 2014. The company announced that Mr. Gordon James Hall has agreed to step down as Non-Executive Director with effect from 31 March 2014.

EKF Diagnostics Holdings plc, Special/Extraordinary Shareholders Meeting, Apr 11, 2014

EKF Diagnostics Holdings plc, Special/Extraordinary Shareholders Meeting, Apr 11, 2014., at 10:30 GMT Standard Time. Location: Canaccord Genuity Limited. Agenda: To issue of new ordinary shares of the company; and to consider disapplication of pre-emption rights;.

EKF Diagnostics Holdings plc Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2013

EKF Diagnostics Holdings plc reported audited consolidated earnings results for the year ended December 31, 2013. For the year, the company reported operating profit was £2.401 million against £0.204 million a year ago. EBITDA before exceptional items and share-based payment was £4.824 million against £3.202 million a year ago. Profit before income tax was £0.607 million against loss of £0.196 million a year ago. Loss from continuing operations was £0.893 million or £0.41 per basic and diluted share against profit from continuing operations of £0.410 million or £0.09 per basic and diluted share a year ago. Profit attributable to owners of the parent was £1.126 million against profit of £1.830 million a year ago. Net cash generated by operating activities was £2.007 million against £1.599 million a year ago. Purchase of property, plant and equipment was £1.185 million against £0.961 million a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKF:LN 35.00 GBp +1.75

EKF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EKF.
View Industry Companies

Industry Analysis


Industry Average

Valuation EKF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.9x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.4x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EKF DIAGNOSTICS HOLDINGS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at